NEW YORK – Roche on Thursday said it will initiate a new global pivotal Phase III trial evaluating the Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec), data from which ...

Roche (RHHBY) announced on Thursday that it is initiating a new Phase 3 trial for Elevidys, a treatment it developed with Sarepta Therapeutics (SRPT) for the muscle-wasting disorder. Duchenne muscular ...

Roche is launching a new global phase 3 trial for the controversial Duchenne muscular dystrophy gene therapy Elevidys in another push for European approval. Rather than relying on patient groups to ...

The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne ...

Upsher-Smith Laboratories has launched two new websites to support people with Duchenne muscular dystrophy (DMD) who are taking its recently introduced corticosteroid therapy Kymbee (deflazacort). One ...

BOSTON, April 16, 2026 (GLOBE NEWSWIRE)-- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company developing next-generation cardiovascular therapeutics, and its clinical development ...

I’ve been fighting Duchenne muscular dystrophy for 40 years. My brothers Angelo and Antonio died from it at ages 20 and 22, respectively. Antonio died in 2015, when my son Ryu was barely a toddler … ...

Mesoblast (MESO) added ~6% in the premarket on Wednesday after the FDA cleared its Investigational New Drug application that sought approval to conduct a study to test its cell therapy, Ryoncil, in ...

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) ...

Mast, who has reported extensively on rare diseases for four years, spoke with Debra and Hawken Miller more than six times over the last eight months and interviewed more than a dozen other advocates, ...